USD10
SLDB azioni
Informazioni su Solid BiosciencesSolid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
USD10
SLDB azioni
Informazioni su Solid BiosciencesSolid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
Dati insufficienti
Capitalizzazione di mercato
699,56 Mln USD
PREZZO DI APERTURA
7,73 USD
MINIMO (1 anno)
2,41 USD
MASSIMO (1 anno)
8,72 USD
MINIMO (24H)
7,05 USD
MASSIMO (24 ore)
7,92 USD
VOLUME (24 ore)
826,64K USD
28,27%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | 7,73 USD | |
1 giorno | 7,11 USD | 0,00% |
1 settimana | 6,92 USD | |
1 mese | 6,21 USD | |
1 anno | 3,70 USD |